ZIDOVUDINE

Post-LOE

zidovudine

Aurobindo Pharma

ANDAORALSOLUTION

Approved

Sep 2005

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

ZIDOVUDINE (zidovudine) by Aurobindo Pharma is nucleoside reverse transcriptase inhibitors [moa]. Approved for maternal-fetal hiv-1 transmission [see ], combination with other antiretroviral agents for the treatment of hiv-1 infection. First approved in 2005.

Drug data last refreshed 21h ago

Mechanism of Action

Nucleoside Reverse Transcriptase Inhibitors

Pharmacologic Class:

Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Indications (1)

combination with other antiretroviral agents for the treatment of HIV-1 infection

Clinical Trials (20)

NCT00000897N/ACompleted

A Study to Evaluate the Effects of Different Methods of Birth Control on the Drug Actions of Zidovudine (an Anti-HIV Drug) in HIV-Positive Women and to Compare Zidovudine Metabolism in Men and Women

42 enrolled

HIV Infections

NCT00000963Phase 2Completed

A Study of Dideoxyinosine (ddI) in HIV-Infected Children Who Have Not Had Success With Zidovudine or Who Cannot Take Zidovudine

300 enrolled

HIV Infections

NCT00001112Phase 1Completed

The Safety and Effectiveness of Injections of Human Recombinant Interferon-gamma in Patients With AIDS Who Have Taken Zidovudine

5 enrolled

HIV Infections

NCT00002179Phase 4Completed

The Effectiveness of Indinavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients With No Symptoms of Infection

200 enrolled

HIV Infections

NCT00002280N/ACompleted

A Study of ddI in Children With AIDS Who Have Not Had Success With Zidovudine

HIV Infections

Worked on ZIDOVUDINE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.